SCTIMST develops nitinol-based ASD occlusion deviceFebruary 26, 2020
The Technical Research Centre for Biomedical Devices, under the Biotechnology Department at Sree Chitra Thirunal Institute of Medical Science and Technology (SCTIMST), India. has developed a nitinol based occlusion device for nonsurgical closure of atrial septal defect (ASD), recently.
The researchers have submitted an application in acquiring the Indian patent for the device.
Recently many occlusion devices have been developed globally for the transcatheter closure of ASD. The ASD occlusion device consists of a braided two-lobed structure. A number of wires are braided together and shaped to form the bi-lobed device with the free ends of the wires from both sides of the device being held together.
While device migration and atrial roof erosion are some common issues and risks faced by most of these commonly used ASD devices, the nitinol based occlusion device developed by SCTIMST is aimed to overcome these defects.
The device has been designed with no hub on the left side of the device, ensuring a smooth tissue layer formation over the device in-due course of time after implantation in the left atrium. The hub on the right side has been retained as part of the release mechanism while delivering the device.
An ASD is referred to the formation of a hole in the wall (septum) between the two upper chambers of the heart called the left and right atria respectively. It is one of the most common types of heart disorders that occur congenitally.
The defect occurs during the development of the heart chambers when the growth of the septum might become incomplete causing the formation of defects like ASD and patent foramen ovale (PFO).
Genetics and environmental factors might play a role in the formation of ASD, though some small such defects have a probability of getting closed without any intervention during infancy or early childhood.
Presently the demand for occlusion device is met mainly through imports, and the current price of the device ranges around Rs 60000/- which may be reduced with the approval of SCTIMST occlusion device.